Showing 5341-5350 of 9080 results for "".
- Baylor Dermatologist Offers Anti-Aging Advice in Response to FaceApp Crazehttps://practicaldermatology.com/news/baylor-dermatologist-offers-anti-aging-advice-in-response-to-faceapp-craze/2460097/The FaceApp is taking social media by storm as celebrities and social media users across the nation morph their faces to look decades older. While it is currently being used for comedic purposes, you may have patients asking how to keep the app from turning into reality. Rajani Katta, M
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Bo
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF.
- AAD Honors Chicago Doctors for Multidisciplinary Approach to Eczema Carehttps://practicaldermatology.com/news/aad-honors-chicago-doctors-for-multidisciplinary-approach-to-eczema-care/2460094/Dermatologist Jonathan Silverberg, MD, PhD, MPH, FAAD, and sleep neurologist Hrayr Attarian, MD, were named Patient Care Heroes by the American Academy of Dermatology for teaming up to provide coordinated, multidisciplinary care to patients with eczema. Both physicians practice medicine
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology
- AARS Survey Uncovers Real Impact Of Acne On Young Professionalshttps://practicaldermatology.com/news/aars-survey-uncovers-real-impact-of-acne-on-young-professionals/2460087/Results of a recent American Acne and Rosacea Society (AARS) survey highlight the significant health burden and everyday impact of acne on young professionals. According to the survey of 1,004 men and women between the ages of 22 and 30 conducted by The Harris Poll, many people whose acne persist
- LEO Pharma Completes Acquisition of Bayer’s Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-completes-acquisition-of-bayers-prescription-dermatology-business/2460086/LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition
- Positive Top-Line Results Seen in Study of Crisaborole for Mild to Moderate AD in Young Childrenhttps://practicaldermatology.com/news/positive-top-line-results-seen-in-study-of-crisaborole-of-for-mild-to-moderate-ad-in-young-children/2460085/Pfizer’s crisaborole ointment (Eucrisa) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), according to top-line results from a Phase 4 study (CrisADe CARE 1). The data from the trial are supportive of the primary stud
- Meet truSculpt flex: Cutera’s Solution for Toned Abs, Butts and Thighshttps://practicaldermatology.com/news/meet-trusculpt-flex-cuteras-solution-for-toned-abs-butts-and-thighs/2460084/Cutera is launching the new truSculpt flex, muscle sculpting platform in the United States, and commercial shipments are slated to begin immediately. truSculpt flex is FDA-cleared for the indications of the improvement of abdominal tone, strengt